Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Bevacizumab, and Chemotherapy for Unresectable AFP-Positive Gastric/GEJ Adenocarcinoma
NCT07515625Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07515625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515625.